FORM 4

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)		-								
1. Name and Address of R Turner Heather D	2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (CO ATARA BIOTHE GATEWAY BOULEV	 3. Date of Earliest Transaction (Month/Day/Year) 02/09/2018 4. If Amendment, Date Original Filed(Month/Day/Year) 						A Officer (give title below) Other (specify below) Former EVP, GC & Sec. A S			
(SOUTH SAN FRANC										
(City) (State) (Zip)	Table I - Non-Derivative Securities Acqu						ired, Disposed of, or Beneficially Owned		
1.Title of Security (Instr. 3)	y 2. Transaction Date 2A. Deemed 3. Transaction 4. Securities Acqu Date Execution Date, if Code (A) or Disposed of (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5)		d of (D)	5. Amount of Securities 6. 7. Natu Beneficially Owned Following Ownership of Indir Reported Transaction(s) Form: Benefic (Instr. 3 and 4) Direct (D) Ownership						
		(Wondi/Day/Tear)	Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	
Common Stock	02/09/2018		S <u>(1)</u>		4,596	D	\$ 36.63 (2)	77,112	D	
Common Stock	02/09/2018		S <u>(1)</u>		4,123	D	\$ 37.38 (<u>3)</u>	72,989	D	
Common Stock	02/09/2018		S <u>(1)</u>		600	D	\$ 38.63 (4)	72,389	D	
Common Stock	02/09/2018		S <u>(1)</u>		733	D	\$ 39.66 (5)	71,656	D	
Common Stock	02/09/2018		S <u>(1)</u>		600	D	\$ 40.62 (6)	71,056	D	
Common Stock	02/09/2018		S ⁽¹⁾		1,562	D	\$ 41.69 (7)	69,494	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-

02)

uired, Disposed of, or Beneficially Owned wition A an

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Own	ne
(e.g., puts, calls, warrants, options, convertible securities)	

(e.g., puts, cans, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.	5.	Numbe	r 6. Date Exe	rcisable	7. Tit	tle and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction	1 of		and Expirati	ion Date	Amo	unt of	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code	De	rivativ	e (Month/Day	/Year)	Unde	rlying	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Se	curities			Secu	rities	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative				Ac	quired			(Instr	: 3 and		Owned	Security:	(Instr. 4)
	Security				(A) or			4)			Following	Direct (D)	
					Di	sposed						Reported	or Indirect	
						(D)						Transaction(s)	< / </td <td></td>	
						str. 3,						(Instr. 4)	(Instr. 4)	
					4, :	and 5)								
							-							
										Amount				
							Date	Expiration		or Number				
							Exercisable	Date		0				
				Code V	. (A	(D)				of Shares				
				Coue v	(A	(D)				Shares				

Reporting Owners

	Describe Orace News (Address	Relationships							
Reporting Owner Name / Address		Director	10% Owner	Officer	Other				
	Turner Heather D								
	C/O ATARA BIOTHERAPEUTICS, INC.			Former EVP, GC & Sec.					
	611 GATEWAY BOULEVARD, SUITE 900			Former EVP, OC & Sec.					

SOUTH SAN FRANCISCO, CA 94080	
Signatures	
/s/ David Tucker, Attorney-in-Fact for Heather D. Turner	02/12/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted September 23, 2016.
- (2) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$36.00 to \$37.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$37.05 to \$38.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (4) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$38.10 to \$39.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (5) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$39.15 to \$39.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (6) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$40.20 to \$41.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (7) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$41.35 to \$41.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.